Swiss National Bank boosted its stake in Agios Pharmaceuticals Inc. (NASDAQ:AGIO) by 29.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 47,560 shares of the biopharmaceutical company’s stock after buying an additional 10,800 shares during the period. Swiss National Bank owned 0.13% of Agios Pharmaceuticals worth $1,993,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Envestnet Asset Management Inc. boosted its stake in Agios Pharmaceuticals by 32.6% in the first quarter. Envestnet Asset Management Inc. now owns 2,769 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 680 shares during the period. BlackRock Inc. boosted its stake in Agios Pharmaceuticals by 373.3% in the first quarter. BlackRock Inc. now owns 3,602 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 2,841 shares during the period. Royal Bank of Canada boosted its stake in Agios Pharmaceuticals by 65.0% in the first quarter. Royal Bank of Canada now owns 4,465 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 1,759 shares during the period. Public Employees Retirement Association of Colorado boosted its stake in Agios Pharmaceuticals by 1.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 6,110 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 82 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Agios Pharmaceuticals during the first quarter worth approximately $318,000. 93.20% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) traded up 4.94% on Wednesday, reaching $52.29. 947,305 shares of the company traded hands. The firm’s market capitalization is $1.99 billion. The stock has a 50-day moving average price of $41.82 and a 200 day moving average price of $45.07. Agios Pharmaceuticals Inc. has a 1-year low of $33.50 and a 1-year high of $89.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.99. Agios Pharmaceuticals had a negative return on equity of 47.69% and a negative net margin of 320.33%. The company earned $6.98 million during the quarter, compared to analysts’ expectations of $39.62 million. During the same quarter in the prior year, the business posted ($0.85) EPS. The company’s revenue for the quarter was down 47.2% compared to the same quarter last year. Analysts anticipate that Agios Pharmaceuticals Inc. will post ($5.04) EPS for the current fiscal year.

A number of brokerages have issued reports on AGIO. Goldman Sachs Group Inc. reissued a “hold” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a report on Monday, June 13th. Janney Montgomery Scott reissued a “neutral” rating and set a $47.00 target price (down previously from $52.00) on shares of Agios Pharmaceuticals in a report on Monday, June 13th. JPMorgan Chase & Co. raised shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $50.00 to $62.00 in a report on Friday, June 10th. Cowen and Company reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, May 24th. Finally, Vetr cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 target price on the stock. in a report on Tuesday, June 7th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.44.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $41.88, for a total value of $104,867.52. Following the sale, the director now owns 125,921 shares in the company, valued at $5,273,571.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.55% of the stock is currently owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc. (NASDAQ:AGIO).

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.